


TCD Biochemical Society

Dr Rebecca Coll, PhD
Queen's University Belfast



“Targeting the NLRP3 inflammasome for the treatment of inflammatory diseases”

Thursday 14th November at 1pm in room 5.16 (FRED), TBSI
Refreshments served from 12.45 in 6.07



TCD Biochemical Society

Dr Rebecca Coll, PhD
Queen's University Belfast



Research Highlights

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition, *Nature Chemical Biology*, 2019.

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease, *Nature Medicine*, 2015.

The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes, *PLoS One*, 2013.